Skip to content

John Yonchuk

  • Translational Scientist/Clinical Study Manager
  • GlaxoSmithKline USA
  • 2h-indexImpact measure calculated using publication and citation counts. Updated daily.
  • 50CitationsNumber of citations received by John's publications. Updated daily.

Other IDs

Co-authors (51)

Publications (5)

  • Characterization of the Potent, Selective Nrf2 Activator, 3-(Pyridin-3-Ylsulfonyl)-5-(Trifluoromethyl)-2H-Chromen-2-One, in Cellular and In Vivo Models of Pulmonary Oxidative Stress

    • Yonchuk J
    • Foley J
    • Bolognese B
    • et al.
    N/AReaders
    0Citations
    Get full text
  • Danirixin: A Reversible and Selective Antagonist of the CXC Chemokine Receptor 2

    • Busch-Petersen J
    • Carpenter D
    • Burman M
    • et al.
    N/AReaders
    2Citations
    Get full text
  • Identification and characterisation of a salt form of Danirixin with reduced pharmacokinetic variability in patient populations

    • Bloomer J
    • Ambery C
    • Miller B
    • et al.
    N/AReaders
    0Citations
    Get full text
  • Monoacidic Inhibitors of the Kelch-like ECH-Associated Protein 1: Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1:NRF2) Protein-Protein Interaction with High Cell Potency Identified by Fragment-Based Discovery.

    • Davies T
    • Wixted W
    • Coyle J
    • et al.
    N/AReaders
    N/ACitations
    Get full text
  • Circulating soluble receptor for advanced glycation end products (sRAGE) as a biomarker of emphysema and the RAGE axis in the lung.

    • Yonchuk J
    • Silverman E
    • Bowler R
    • et al.
    N/AReaders
    N/ACitations
    Get full text

Professional experience

Translational Scientist/Clinical Study Manager

GlaxoSmithKline USA

April 2000 - Present

Education

Master of Science Pharmacology

Thomas Jefferson University

August 2003 - November 2008(5 years)

Bachelor of Science Biology

Pennsylvania State University

August 1994 - May 1999(5 years)